Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36526616.
- Also identified by DOI 10.1038/s41467-022-34655-1 and PMC identifier 9758236.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epitopes in COVID-19 convalescents might differ according to the course of the disease. We establish a cellular screening method that uses artificial antigen presenting cells, expressing HLA-A<sup>*</sup>24:02, the costimulatory molecule 4-1BBL, SARS-CoV-2 structural proteins S, M, and N and non-structural proteins ORF3a and nsp6/ORF1a. The screen implicates SARS-CoV-2 M protein as a frequent target of IFNγ secreting CD8<sup>+</sup> T cells, and identifies M<sub>198-206</sub> as an immunoprevalent epitope in our cohort of HLA-A<sup>*</sup>24:02 positive convalescent COVID-19 patients recovering from mild, moderate and severe disease. Further exploration of M<sub>198-206</sub>-specific CD8<sup>+</sup> T cells with single cell RNA sequencing reveals public TCRs in virus-specific CD8<sup>+</sup> T cells, and shows an exhausted phenotype with less differentiated status in cells from the severe group compared to cells from the moderate group. In summary, this study describes a method to identify T cell epitopes, indicate that dysfunction of virus-specific CTLs might be an important determinant of clinical outcomes.
Medical subject headings
- CD8-Positive T-Lymphocytes
- COVID-19